Back to results
US 12,215,159 B2Granted
Anti-CD161 antibodies and uses thereof
AssigneeImmunitas Therapeutics, Inc.
InventorsAlison Tisdale, Uli Bialucha, George Punkosdy, Alexandria Fusco, Frano Irvine, Emily Rosentrater, Elizabeth Scanlon, Michael Battles
Life of this patent
Estimating the term…
Abstract
The invention relates generally to anti-CD161 antibodies, pharmaceutical compositions comprising such antibodies, and methods of using such antibodies for treating disorders associated with or mediated by CD161, for example, certain cancers. In addition, the invention also relates to expression vectors and host cells for making these antibodies.
Claims30
An isolated anti-CD161 antibody comprising:
- a heavy chain variable region comprising CDR-H1, CDR-H2, and CDR-H3 sequences, wherein:
- (a) the amino acid sequence of CDR-H1 comprises the amino acid sequence set forth in SEQ ID NO:
- 72;
- (b) the amino acid sequence of CDR-H2 comprises the amino acid sequence set forth in SEQ ID NO:
- 73;
- (c) the amino acid sequence of CDR-H3 comprises the amino acid sequence set forth in SEQ ID NO:
- 74;
- and
- a light chain variable region comprising CDR-L1, CDR-L2 and CDR-L3 sequences, wherein:
- (d) the amino acid sequence of CDR-L1 comprises the amino acid sequence set forth in SEQ ID NO:
- 76;
- (e) the amino acid sequence of CDR-L2 comprises the amino acid sequence set forth in SEQ ID NO:
- 77;
- and
- (f) the amino acid sequence of CDR-L3 comprises the amino acid sequence set forth in SEQ ID NO:
- 78.
13 more elements
Dependencies are inferred from the claim text.